title: Human immunodeficiency virus type 1 envelope-stimulated interleukin-2 production and survival of infected children with severe and mild clinical disease.
abstract: Interleukin (IL)-2 production after stimulation with human immunodeficiency virus type 1 (HIV-1) envelope (Env) peptides, tetanus toxoid, and phytohemagglutinin was measured in peripheral blood mononuclear cells (PBMC) from 25 HIV-1-infected children with mild and 24 with severe clinical disease and from 15 uninfected children. Env-specific IL-2 production was detected in PBMC of 26.5% of HIV-1-infected children but in none of the uninfected. The absence of Env-specific responses at enrollment among infected children was associated with a 6-fold increased risk of mortality within a year, adjusting for clinical severity (P=.04). Among those with severe clinical disease, Env-stimulated IL-2 reactivity in PBMC was negatively correlated with HIV-1 RNA copy numbers in plasma at enrollment and was positively correlated with CD4 T cell percentages 1 year later. HIV-specific cellular immune responses may play a role in containing progression of HIV-1 infection in children, despite early deficits in cell-mediated immunity.
authors.affiliation: Gertrude H. Sergievsky Center, College of Physicians and Surgeons, and Division of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York 10032, USA. lk24@columbia.edu
authors.forename: L
authors.initials: L
authors.lastname: Kuhn
authors.forename: T M
authors.initials: TM
authors.lastname: Meyers
authors.forename: S
authors.initials: S
authors.lastname: Meddows-Taylor
authors.forename: K
authors.initials: K
authors.lastname: Simmank
authors.forename: G G
authors.initials: GG
authors.lastname: Sherman
authors.forename: C T
authors.initials: CT
authors.lastname: Tiemessen
mesh_terms: D002648:Child; D002675:Child, Preschool; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D015686:Gene Products, env / Q000276:immunology*; D015658:HIV Infections / Q000276:immunology* / Q000401:mortality / Q000503:physiopathology; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007376:Interleukin-2 / Q000096:biosynthesis*; D008213:Lymphocyte Activation; D008214:Lymphocytes / Q000187:drug effects / Q000276:immunology* / Q000821:virology; D008297:Male; D010835:Phytohemagglutinins; D011336:Probability; D012367:RNA, Viral / Q000097:blood; D012016:Reference Values; D013019:South Africa; D015996:Survival Rate; D013745:Tetanus Toxoid / Q000276:immunology; D013997:Time Factors; D019562:Viral Load
chemical_list: D015686:Gene Products, env; D007376:Interleukin-2; D010835:Phytohemagglutinins; D012367:RNA, Viral; D013745:Tetanus Toxoid